当前位置: 首页 >> 检索结果
501. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
作者: G Karanikolas.;D Charalambopoulos.;G Vaiopoulos.;A Andrianakos.;A Rapti.;D Karras.;E Kaskani.;P P Sfikakis.
来源: Rheumatology (Oxford). 2008年47卷9期1384-8页
To assess the efficacy and safety of anakinra (ANK) as an add-on therapy in RA patients with inadequate response to monotherapy with non-biological DMARDs.
502. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation.
作者: E K Li.;J F Griffith.;V W Lee.;Y-X Wang.;T K Li.;K K Lee.;L-S Tam.
来源: Rheumatology (Oxford). 2008年47卷9期1358-63页
To examine the short-term efficacy and safety of MTX in combination with infliximab compared with infliximab and placebo in the treatment of AS using MRI to monitor its effect.
503. Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study [ISRCTN: 79353052].
作者: E Castelnuovo.;P Cross.;S Mt-Isa.;A Spencer.;M Underwood.; .
来源: Rheumatology (Oxford). 2008年47卷7期1077-81页
Advice to use topical or oral NSAIDs is equally effective for the treatment of knee pain in older people. The ingredient cost of topical preparations is typically more than oral preparations, but could save costs because they have fewer adverse effects. A cost-utility study is needed to decide on their comparative cost effectiveness.
504. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort.
作者: S Durán-Barragán.;G McGwin.;L M Vilá.;J D Reveille.;G S Alarcón.; .
来源: Rheumatology (Oxford). 2008年47卷7期1093-6页
To examine if angiotensin-converting enzyme (ACE) inhibitor use delays the occurrence of renal involvement and decreases the risk of disease activity in SLE patients.
505. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis.
作者: H Forsblad d'Elia.;R Pullerits.;H Carlsten.;M Bokarewa.
来源: Rheumatology (Oxford). 2008年47卷7期1082-7页
The aim of this study was to investigate associations between serum levels of resistin, an adipokine and markers of inflammation, bone metabolism, plasma lipids and kidney function in post-menopausal RA patients and to evaluate if HRT during 2 yrs affected resistin levels.
506. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept.
作者: J C Cole.;T Li.;P Lin.;R MacLean.;G V Wallenstein.
来源: Rheumatology (Oxford). 2008年47卷7期1044-50页
Quality of life (QoL) improvement is important to demonstrate in RA clinical trials, but can be abstract. More meaningful measures of QoL include medical expenditure and job loss, aspects that have marked importance for RA patients, physicians and society. We re-examined previous positive QoL findings for abatacept over placebo by converting existing QoL measures into estimated medical expenditure and estimated likelihood of job loss.
507. Single-point acupuncture and physiotherapy for the treatment of painful shoulder: a multicentre randomized controlled trial.
作者: J Vas.;C Ortega.;V Olmo.;F Perez-Fernandez.;L Hernandez.;I Medina.;J M Seminario.;A Herrera.;F Luna.;E Perea-Milla.;C Mendez.;F Madrazo.;C Jimenez.;M A Ruiz.;I Aguilar.
来源: Rheumatology (Oxford). 2008年47卷6期887-93页
Evaluate the efficacy of acupuncture associated with physiotherapy for patients with painful shoulder.
508. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study.
作者: Z de Jong.;M Munneke.;V Vilim.;A H Zwinderman.;H M Kroon.;H K Ronday.;W F Lems.;B A C Dijkmans.;F C Breedveld.;T P M Vliet Vlieland.;J M W Hazes.;J Degroot.
来源: Rheumatology (Oxford). 2008年47卷6期868-71页
To investigate the utility of serum COMP level measurements as a predictor of future damage of the weight-bearing (large) joints in RA patients participating in intensive exercise.
509. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
作者: F Cantini.;L Niccoli.;C Nannini.;E Cassarà.;P Pasquetti.;I Olivieri.;C Salvarani.
来源: Rheumatology (Oxford). 2008年47卷6期872-6页
To evaluate the frequency and duration of clinical remission in patients with PsA.
510. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
作者: Y Tamimoto.;T Horiuchi.;H Tsukamoto.;J Otsuka.;H Mitoma.;Y Kimoto.;H Nakashima.;K Muta.;Y Abe.;C Kiyohara.;A Ueda.;K Nagasawa.;S Yoshizawa.;T Shimoda.;M Harada.
来源: Rheumatology (Oxford). 2008年47卷6期821-7页
Accumulating evidence suggests that B-cell depletion therapy by rituximab may be effective for autoimmune disorders. However, an optimal dose of rituximab and a mechanism of its action remain to be established. We performed a dose-escalation study for treatment of Japanese patients with autoimmune diseases including eight with SLE and one with Evans' syndrome.
511. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.
This study assessed the utility of rituximab for the therapy of RA in a non-academic environment in a group of cases where anti-TNF was either not available or relatively contraindicated.
512. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis.
作者: B Galarraga.;M Ho.;H M Youssef.;A Hill.;H McMahon.;C Hall.;S Ogston.;G Nuki.;J J F Belch.
来源: Rheumatology (Oxford). 2008年47卷5期665-9页
Dose-dependant gastrointestinal and cardiovascular side-effects limit the use of NSAIDs in the management of RA. The n-3 essential fatty acids (EFAs) have previously demonstrated some anti-inflammatory and NSAID-sparing properties. The objective of this study was to determine whether cod liver oil supplementation helps reduce daily NSAID requirement of patients with RA.
513. Extracorporeal shockwave therapy shows regeneration in hip necrosis.
作者: C-J Wang.;F-S Wang.;J-Y Ko.;H-Y Huang.;C-J Chen.;Y-C Sun.;Y-J Yang.
来源: Rheumatology (Oxford). 2008年47卷4期542-6页
The effect of shockwave in osteonecrosis of the femoral head (ONFH) is poorly understood. The purpose of this study was to investigate the regeneration effects of shockwave in ONFH.
514. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
作者: M Vera-Llonch.;E Massarotti.;F Wolfe.;N Shadick.;R Westhovens.;O Sofrygin.;R Maclean.;Y Yuan.;G Oster.
来源: Rheumatology (Oxford). 2008年47卷4期535-41页
To assess cost-effectiveness of abatacept in patients with moderately to severely active RA and inadequate response to MTX.
515. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion.
作者: R Perricone.;C De Carolis.;B Kröegler.;E Greco.;R Giacomelli.;P Cipriani.;L Fontana.;C Perricone.
来源: Rheumatology (Oxford). 2008年47卷5期646-51页
We aimed to test the maternal and fetal outcome of SLE patients who suffered from recurrent spontaneous abortion (RSA) treated with intravenous immunoglobulin (IVIg) alone during pregnancy and whether the clinical response to IVIg treatment is accompanied by modifications of SLE-associated antibodies and of complement levels.
516. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
作者: L E Kristensen.;M C Kapetanovic.;A Gülfe.;M Söderlin.;T Saxne.;P Geborek.
来源: Rheumatology (Oxford). 2008年47卷4期495-9页
To identify factors predicting response to first TNF blocking treatment course in patients with established RA with a special focus on gender differences.
517. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
作者: J A Karlsson.;L E Kristensen.;M C Kapetanovic.;A Gülfe.;T Saxne.;P Geborek.
来源: Rheumatology (Oxford). 2008年47卷4期507-13页
To study treatment response rates of RA patients undergoing second- and third-line anti-TNF therapy and to identify baseline predictors of response to second-line treatment.
518. Low-intensity pulsed ultrasound for chronic patellar tendinopathy: a randomized, double-blind, placebo-controlled trial.
作者: S J Warden.;B R Metcalf.;Z S Kiss.;J L Cook.;C R Purdam.;K L Bennell.;K M Crossley.
来源: Rheumatology (Oxford). 2008年47卷4期467-71页
Patellar tendinopathy (PT) is a common and significant clinical condition for which there are few established interventions. One intervention that is currently being used clinically to manage PT symptoms is the introduction of low-intensity pulsed ultrasound (LIPUS). The aim of this study was to investigate the clinical efficacy of LIPUS in the management of PT symptoms.
519. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
作者: P García de la Peña-Lefebvre.;S Rodríguez Rubio.;M Valero Expósito.;L Carmona.;M L Gámir Gámir.;J Beltrán Gutiérrez.;C Díaz-Miguel.;J Orte Martínez.;A C Zea Mendoza.
来源: Rheumatology (Oxford). 2008年47卷4期464-6页
Our objective was to evaluate the efficacy and tolerability of bosentan in patients with systemic sclerosis (SSc) who develop ulcers and healed ulcers. We also wanted to analyse the effect of bosentan on other skin and general outcome measurements.
520. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
作者: C Gordon.;D J Wallace.;S Shinada.;K C Kalunian.;L Forbess.;G D Braunstein.;M H Weisman.
来源: Rheumatology (Oxford). 2008年47卷3期334-8页
Androgen deficiency has been associated with the development of systemic lupus erythematosus (SLE). The aim of this study was to test the efficacy of testosterone patches vs placebo in female SLE patients with baseline mild-to-moderate disease activity in a randomized, double-blind, single-centre placebo-controlled trial.
|